IGF2AS (C-12): sc-161725



The Power to Question

BACKGROUND

The insulin gene family, comprised of insulin, Relaxin and insulin-like growth factors I and II (IGF-I and IGF-II), encodes a group of structurally related polypeptides whose biological functions have diverged. The IGFs, including IGF-I and IGF-II, are critical regulators of cell proliferation and most of the growth promoting properties of both ligands are mediated by the IGF-I receptor, designated IGF-IR. IGF-I expression is regulated by growth hormone and mediates postnatal growth, while IGF-II is induced by placental lactogen during prenatal development. IGF2AS (insulin-like growth factor 2 antisense), also known as PEG8, is a 168 amino acid protein that is expressed at high levels in fetal kidney and is encoded by a gene which is anti-sense to the gene encoding human IGF-II. Defects in the gene encoding IGF2AS are associated with ovarian, breast and Wilms tumor tissues, suggesting a possible role for IGF2AS in carcinogenesis.

REFERENCES

- Ogawa, O., et al. 1993. Relaxation of Insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362: 749-751.
- Okutsu, T., et al. 2000. Expression and imprinting status of human PEG8/ IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors. J. Biochem. 127: 475-483.
- 3. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 610146. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- Vu, T.H., et al. 2003. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res. 63: 1900-1905.
- 5. Yang, J.M., et al. 2003. Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. J. Gastroenterol. Hepatol. 18: 296-301.
- Devaney, J.M., et al. 2007. IGF-II gene region polymorphisms related to exertional muscle damage. J. Appl. Physiol. 102: 1815-1823.
- 7. Hosgood, H.D., et al. 2008. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 29: 1938-1943.
- 8. Coan, P.M., et al. 2008. Disproportional effects of lgf2 knockout on placental morphology and diffusional exchange characteristics in the mouse. J. Physiol. 586: 5023-5032.

CHROMOSOMAL LOCATION

Genetic locus: IGF2AS (human) mapping to 11p15.5.

SOURCE

IGF2AS (C-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of IGF2AS of human origin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-161725 P, (100 μg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

IGF2AS (C-12) is recommended for detection of IGF2AS of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IGF2AS siRNA (h): sc-96884, IGF2AS shRNA Plasmid (h): sc-96884-SH and IGF2AS shRNA (h) Lentiviral Particles: sc-96884-V.

Molecular Weight of IGF2AS: 18 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat lgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat lgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat lgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**